Skip to Content

Switching from biology treatment of AD to a JAK inhibitor resulted in improved efficacy

In this MEDtalk Andrew Blauvelt, dermatologist, presents the results of switching from dupilumab to upadacitinib in moderate to severe atopic dermatitis. This resulted in improved efficacy with higher rates of skin clearance and itch improvement when compared to week 24 response rates.

Andrew Blauvelt

Få tillgång

Om du är läkare, sjuksköterska eller annan vårdpersonal kan du komma åt hela artikeln genom att skapa en profil på BestPractice Nordic.

Back to top